Valeant Pharmaceuticals Intl Inc (VRX) PT Lowered to C$39.00 at Royal Bank Of Canada
Valeant Pharmaceuticals Intl Inc (TSE:VRX) had its price target lowered by Royal Bank Of Canada from C$47.00 to C$39.00 in a report released on Wednesday, StockTargetPrices.com reports. The firm currently has a sector perform rating on the specialty pharmaceutical company’s stock.
Several other brokerages also recently weighed in on VRX. TD Securities reaffirmed a buy rating and issued a C$38.00 target price on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, August 10th. Scotiabank lowered their target price on shares of Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a sector perform rating on the stock in a report on Monday, July 25th.
Shares of Valeant Pharmaceuticals Intl (TSE:VRX) opened at 24.42 on Wednesday. The firm’s market cap is $8.49 billion. The firm has a 50-day moving average of $29.16 and a 200-day moving average of $32.91. Valeant Pharmaceuticals Intl has a 12-month low of $18.41 and a 12-month high of $165.77.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Stock Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related stocks with our FREE daily email newsletter.